RheumaGen Announces Oral Presentation on HLA Gene-Editing Preclinical Data for Lead Autoimmune Disease Program at ACR Convergence 2025

AURORA, Colo., Oct. 1, 2025 /PRNewswire/ -- RheumaGen, Inc., a cell and gene therapy company engineering a new class of therapeutics for major autoimmune diseases, today announced that a human leukocyte antigen (HLA) gene-editing abstract has been selected for oral presentation at the American College of Rheumatology (ACR) Convergence 2025, taking place October 24-29, 2025, in Chicago.

Vibha Jha, Ph.D., from the Center for Clinical Immunology at the University of Colorado, will deliver an oral presentation highlighting preclinical research on RheumaGen's novel HLA gene-editing approach targeting Class II HLA-DRB1*04:01, the strongest genetic risk factor for rheumatoid arthritis (RA). The results demonstrate that RheumaGen's approach has the potential to be used as a gene therapy to safely halt the progression of RA in patients carrying this allele variant.

Oral Presentation Details:

Title: Gene Editing of HLA-Class II DRB1*04:01 at Position 82 Abrogates Binding of Citrullinated Arthritogenic Peptides and Collagen
Session: Genetics, Genomics & Proteomics
Date and Time: Monday, October 27, 2025, 3:45-4:00 p.m. CT
Abstract Number: 1701
Presenter: Vibha Ja, Ph.D., University of Colorado Anschutz Medical Campus

A copy of the presentation abstract is now available online.

About RheumaGen, Inc.
RheumaGen is a private biotechnology company engineering a new class of therapeutics to cure common autoimmune diseases. RheumaGen focuses on editing the human leukocyte antigen (HLA), or "immune gene," to develop one-time, curative cell and gene therapies. RheumaGen is headquartered in Aurora, Colorado. For more information, please visit rheumagen.com.

About ClinImmune
Founded in 1997 by Dr. Brian Freed, the ClinImmune Center for Clinical Immunology has become a cornerstone of transplant and cell-therapy excellence. Located on the University of Colorado Anschutz Medical Campus, the Center operates a state-of-the-art, 25,000-square-foot cGMP facility staffed by ~80 highly trained professionals. Since its inception, ClinImmune has facilitated more than 10,000 organ and stem-cell transplants and currently supports dozens of clinical trials advancing cell-based therapies. With a steadfast commitment to scientific rigor and patient care, ClinImmune continues to drive innovation in immunology and regenerative medicine. For more information, please visit clinimmune.com

SOURCE RheumaGen, Inc.